Monitor OTLK's stock price closely ahead of the July 16 special meeting, if it holds above $1.00, the reverse split may be less urgent; if it drifts lower, the split becomes more likely. The delisting risk has receded for now but remains a latent overhang.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $1.57entry
- T+1 · 4mo ago −1.27%α −0.51% · $1.55
- T+5 · 4mo ago −7.01%α −6.45% · $1.46
- T+20 · 3mo ago −35.03%α −37.46% · $1.02
- T+60 · 6w ago −62.07%α −64.70% · $0.5955
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics filed a DEFA14A supplement to its proxy statement, updating shareholders that it regained Nasdaq minimum bid price compliance as of June 25, 2026 after a prior delisting notice, but warning that the stock closed at only $1.68 on July 9 and remains vulnerable to re-listing risk if price falls below $1.00 again. The supplement emphasizes that the reverse stock split proposal remains relevant as a contingency against future non-compliance.
Key Financial Metrics
Key Facts
- Outlook Therapeutics received a Nasdaq delisting notice on February 18, 2026 for failing to maintain $1.00 minimum bid price
- On June 26, 2026, Nasdaq confirmed the company regained compliance as closing bid price was ≥ $1.00 for 10 consecutive business days (June 11–25, 2026)
- As of July 9, 2026, the closing price was $1.68 per share; the company warns it could decline below $1.00 again
- The board's reverse stock split authorization (Proposal No. 3) remains a contingency tool; if not implemented within one year of the meeting, further shareholder approval will be needed
Financial Impact
No financial figures disclosed; the filing addresses listing compliance only
Risk Factors
- Stock price could fall below $1.00 again, triggering renewed delisting proceedings
- If reverse split is implemented, it may cause temporary volatility and potential selling pressure
- Any failure to maintain Nasdaq listing standards could materially impair liquidity and capital access
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-082361 |
| Document: 0001104659-26-082361-index-headers.html | 0001104659-26-082361 |
| Document: 0001104659-26-082361-index.html | 0001104659-26-082361 |
| Document: 0001104659-26-082361.txt | 0001104659-26-082361 |
Track record
37 reports on OTLK
13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers